HRP20210537T1 - Upotreba inhibitora faktora induciranog hipoksijom - Google Patents

Upotreba inhibitora faktora induciranog hipoksijom Download PDF

Info

Publication number
HRP20210537T1
HRP20210537T1 HRP20210537TT HRP20210537T HRP20210537T1 HR P20210537 T1 HRP20210537 T1 HR P20210537T1 HR P20210537T T HRP20210537T T HR P20210537TT HR P20210537 T HRP20210537 T HR P20210537T HR P20210537 T1 HRP20210537 T1 HR P20210537T1
Authority
HR
Croatia
Prior art keywords
echinomycin
hypoxia
myeloid leukemia
inducible factor
factor inhibitors
Prior art date
Application number
HRP20210537TT
Other languages
English (en)
Inventor
Yang Liu
Yin Wang
Yan Liu
Sami N. Malek
Pan ZENG
Original Assignee
Oncoimmune Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc. filed Critical Oncoimmune Inc.
Publication of HRP20210537T1 publication Critical patent/HRP20210537T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (4)

1. Farmaceutski pripravak koji sadrži ehinomicin za uporabu u liječenju akutne mijeloične leukemije.
2. Farmaceutski pripravak koji sadrži ehinomicin za uporabu u induciranju akutne remisije mijeloične leukemije kod čovjeka.
3. Farmaceutski pripravak koji sadrži ehinomicin za uporabu u prevenciji budućeg recidiva akutne mijeloične leukemije kod čovjeka tijekom remisije akutne mijeloične leukemije.
4. Farmaceutski pripravak koji sadrži ehinomicin za uporabu u skladu s bilo kojim od patentnih zahtjeva 1-3, naznačen time što je ehinomicin jedini aktivni farmaceutski sastojak koji se koristi.
HRP20210537TT 2009-12-04 2021-04-01 Upotreba inhibitora faktora induciranog hipoksijom HRP20210537T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26685609P 2009-12-04 2009-12-04
EP10834883.0A EP2506840B1 (en) 2009-12-04 2010-06-25 Uses of hypoxia-inducible factor inhibitors
PCT/US2010/039910 WO2011068563A1 (en) 2009-12-04 2010-06-25 Uses of hypoxia-inducible factor inhibitors

Publications (1)

Publication Number Publication Date
HRP20210537T1 true HRP20210537T1 (hr) 2021-05-14

Family

ID=44115219

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20210537TT HRP20210537T1 (hr) 2009-12-04 2021-04-01 Upotreba inhibitora faktora induciranog hipoksijom

Country Status (14)

Country Link
US (7) US9427413B2 (hr)
EP (2) EP3892264A3 (hr)
CN (2) CN102791260A (hr)
CA (1) CA2782527C (hr)
CY (1) CY1125365T1 (hr)
DK (1) DK2506840T3 (hr)
ES (1) ES2864743T3 (hr)
HR (1) HRP20210537T1 (hr)
HU (1) HUE053793T2 (hr)
LT (1) LT2506840T (hr)
PL (1) PL2506840T3 (hr)
PT (1) PT2506840T (hr)
SI (1) SI2506840T1 (hr)
WO (1) WO2011068563A1 (hr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011068563A1 (en) 2009-12-04 2011-06-09 Oncoimmune Inc. Uses of hypoxia-inducible factor inhibitors
CN103007293B (zh) * 2012-12-30 2014-04-02 中国人民解放军第三军医大学第一附属医院 具有靶向性的多肽-基因复合物及其制备方法和应用
WO2017031341A1 (en) * 2015-08-19 2017-02-23 Children's Research Institute, Children's National Medical Center Compositions and methods for treating graft versus host disease
WO2017083403A1 (en) 2015-11-10 2017-05-18 Children's Research Institute, Children's National Medical Center Echinomycin formulation, method of making and method of use thereof
US11229657B2 (en) 2017-04-21 2022-01-25 Lunella Biotech, Inc. Targeting hypoxic cancer stem cells (CSCs) with doxycycline: implications for improving anti-angiogenic therapy
EP3612187B1 (en) 2017-04-21 2022-04-13 Lunella Biotech, Inc. Vitamin c and doxycycline: a synthetic lethal combination therapy for eradicating cancer stem cells (cscs)
WO2018213751A1 (en) 2017-05-19 2018-11-22 Lunella Biotech, Inc. Antimitoscins: targeted inhibitors of mitochondrial biogenesis for eradicating cancer stem cells
US12006553B2 (en) 2017-05-19 2024-06-11 Lunella Biotech, Inc. Companion diagnostics for mitochondrial inhibitors
MX2019014806A (es) 2017-06-26 2020-02-10 Lunella Biotech Inc Mitocetoscinas: agentes terapeuticos basados en mitocondrias que fijan como objetivo el metabolismo de cetonas en celulas cancerosas.
CN110669871A (zh) * 2019-10-17 2020-01-10 河北森朗生物科技有限公司 一种慢病毒转导滴度的测定方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643871A (en) 1993-11-23 1997-07-01 Bristol-Meyers Squibb Company Antitumor antibiotics
US6416956B1 (en) * 1999-08-13 2002-07-09 George Washington University Transcription factor, BP1
WO2002034291A2 (en) 2000-10-26 2002-05-02 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hematologic malignancies and multiple drug resistance
AU2004251890B2 (en) * 2003-06-25 2010-09-23 Crucell Holland B.V. Binding molecules for the treatment of myeloid cell malignancies
CN1233844C (zh) * 2003-09-05 2005-12-28 上海第二医科大学附属瑞金医院 HIF－1α在治疗白血病药物的筛选中的应用
AU2005280112B2 (en) * 2004-08-27 2012-07-19 Infinity Pharmaceuticals, Inc. Cyclopamine analogues and methods of use thereof
JP5011277B2 (ja) * 2005-04-06 2012-08-29 アイビーシー・ファーマシューティカルズ・インコーポレーテッド ホモダイマー、ホモテトラマーまたはダイマーのダイマーのからなる安定に連結された複合体を発生させるための方法および使用
US20070212360A1 (en) * 2006-01-17 2007-09-13 Denko Nicholas C Modulation of mitochondrial oxygen consumption for therapeutic purposes
WO2007130037A1 (en) * 2006-05-02 2007-11-15 Emory University Hif-1 inhibitors and methods of use thereof
ES2556677T3 (es) 2006-08-02 2016-01-19 Sunesis Pharmaceuticals, Inc. Utilización combinada de ácido (+)-1,4-dihidro-7-[(3S,4S)-3-metoxi-4-(metilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftiridin-3-carboxílico y citarabina (Ara-C) para el tratamiento de la leucemia
WO2008128169A1 (en) * 2007-04-13 2008-10-23 Abraxis Bioscience, Inc. Sparc and methods of use thereof
WO2009049258A1 (en) * 2007-10-12 2009-04-16 The Johns Hopkins University Compounds for hedgehog pathway blockade in proliferative disorders, including hematopoietic malignancies
WO2011068563A1 (en) 2009-12-04 2011-06-09 Oncoimmune Inc. Uses of hypoxia-inducible factor inhibitors

Also Published As

Publication number Publication date
US20120264697A1 (en) 2012-10-18
HUE053793T2 (hu) 2021-07-28
DK2506840T3 (da) 2021-04-12
US9623070B2 (en) 2017-04-18
EP2506840A4 (en) 2013-07-03
PT2506840T (pt) 2021-04-27
CA2782527A1 (en) 2011-06-09
ES2864743T3 (es) 2021-10-14
EP2506840B1 (en) 2021-01-06
LT2506840T (lt) 2021-06-25
EP2506840A1 (en) 2012-10-10
US20190255140A1 (en) 2019-08-22
US9877998B2 (en) 2018-01-30
CN109224064A (zh) 2019-01-18
US20210161991A1 (en) 2021-06-03
PL2506840T3 (pl) 2021-10-11
US20170035832A1 (en) 2017-02-09
CN102791260A (zh) 2012-11-21
US20180177841A1 (en) 2018-06-28
CA2782527C (en) 2019-09-17
SI2506840T1 (sl) 2021-08-31
US9427413B2 (en) 2016-08-30
US20200147167A1 (en) 2020-05-14
CY1125365T1 (el) 2024-02-16
EP3892264A2 (en) 2021-10-13
WO2011068563A1 (en) 2011-06-09
US20170239315A1 (en) 2017-08-24
EP3892264A3 (en) 2021-12-08

Similar Documents

Publication Publication Date Title
HRP20210537T1 (hr) Upotreba inhibitora faktora induciranog hipoksijom
CY1124486T1 (el) Υποκατεστημενα βενζαμιδια 1,3-θειαζολ-2-υλιου
CL2014002757A1 (es) Compuestos derivados de benzamida para inhibir la actividad de abl1, abl2 y bcr-abl1, composicion farmaceutica; y uso en el tratamiento del cancer.
MD3313850T2 (ro) Noi derivaţi de aminoacizi, procedeu pentru prepararea acestora şi compoziţii farmaceutice care îi conţin
IN2015DN01662A (hr)
CA2894892A1 (en) Boronic acid derivatives and therapeutic uses thereof
EA201101190A1 (ru) Фармацевтическая композиция, включающая линаглиптин и необязательно ингибитор sglt2, и ее применение
MX363717B (es) Compuestos antiviricos para el virus sincitial respiratorio.
CL2014002386A1 (es) Compuesto inhibidor de cinasa de fosfoinositida 3 en forma anhidra cristalina solida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento o prevencion de enfermedades tales como epoc, asma, entre otras.
MX345535B (es) Compuestos tricíclicos parcialmente saturados y métodos para su fabricación y su uso.
JP2014530840A5 (hr)
MX2018000419A (es) Derivados de amida sustituida que tienen actividad multimodal contra el dolor.
CL2012003322A1 (es) Compuestos derivados de benzamida sustituidas; composicion farmacéutica; y uso en el tratamiento del cancer.
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MY173573A (en) Pyridin-4-yl derivatives
CL2014001861A1 (es) Compuestos derivados de bencil sulfonamida, inhibidores de mogat-2; compuesto cristalino; composicion farmaceutica; y su uso en el tratamiento de la hipertrigliceridemia.
AR090806A1 (es) Glucosidos de pirazol y su utilizacion en el tratamiento de la diabetes tipo i y ii
EA201491532A1 (ru) Фармацевтические композиции для использования в комплексной терапии
MX2016004934A (es) Derivados de aminotetralina y aminoindano, composiciones farmaceuticas que los contienen, y su uso en terapia.
RU2010103781A (ru) Противоопухолевые комбинации, содержащие ингибитор vegf и иринотекан
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
UY35211A (es) Compuestos tricíclicos
MX2015007940A (es) Compuestos tricíclicos como inhibidores de cftr.
CL2009000510A1 (es) Compuestos derivados de 1,3,5,6,7,8-hexahidro-furo[3,4-b]quinolina, inhibidores de cetp; proceso de preparacion de los compuestos; composicion farmaceutica; proceso de preparacion de la composicion; y uso en el tratamiento y/o prevencion de trastornos cardiovasculares y trastornos relacionados.
WO2014182789A3 (en) Radiomitigating pharmaceutical formulations